ERBB2 and breast carcinoma: For this purpose, we tested the hypothesis that patients with breast cancer featuring low levels of HER2 had different clinical-pathological characteristics and survival outcome compared with HER2-0 in breast cancer patients routinely treated with neoadjuvant chemotherapy in the largest public comprehensive cancer center of Italy.